

Insulin Resistance and Type 2 Diabetes

Roshan Kumar B^{1*}, Nikitha I¹, Shiva Sharma², Nishikant D³, Rishu T⁴

¹Department of Pharmaceutics, CMR Group of Institutions, Hyderabad, Telangana, India

²Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali, Punjab, India

³Department of Pharmacology, RTM Nagpur University, Nagpur, Maharashtra, India

⁴Department of Biotechnology, Dolphin PG College of Life Sciences, Chandigarh, Punjab, India

Review Article

Received: 02/02/2017

Accepted: 23/02/2017

Published: 28/02/2017

*For Correspondence

Department of Pharmaceutics, CMR College of Pharmacy, CMR Group of Institutions, Hyderabad Medchal Road, Telangana, India.

E-mail: brkumar127@gmail.com

Keywords:

Obesity, Insulin, Diabetes, Glucose

ABSTRACT

As weight problems and diabetes attain epidemic proportions in the developed global, the role of insulin resistance and its outcomes are gaining prominence. Understanding the role of insulin in extensive-ranging physiological strategies and the effects on its synthesis and secretion, alongside its actions from the molecular to the complete body degree, have sizeable implications for a lot [chronic disease](#) visible in Westernised populations nowadays. This overview provides a top level view of insulin, its history, shape, synthesis, secretion, actions and interactions observed with the aid of a discussion of insulin resistance and its associated clinical manifestations. Specific regions of attention include the actions of insulin and manifestations of insulin resistance in precise organs and tissues, physiological, environmental and pharmacological impacts on insulin action and [insulin](#) resistance as well as scientific syndromes associated with insulin resistance. Clinical and useful measures of insulin resistance also are included. Despite our incomplete knowledge of the complicated organic mechanisms of insulin motion and insulin resistance, we want to do not forget the dramatic social modifications of the past century with appreciate to physical hobby, weight loss plan, work, and socialisation and [sleep](#) patterns. Rapid globalisation, urbanisation and industrialisation have spawned epidemics of [obesity](#), diabetes and their attendant co-morbidities, as bodily state of no activity and dietary imbalance unmask latent predisposing genetic trends.

INTRODUCTION

These rely upon poorly understood variations in individual biology and consequently might not be determined with everybody identified with insulin resistance ^[1-6]. Brain fogginess and incapacity to awareness.

High Blood Sugar

Intestinal bloating – most intestinal fuel is made out of carbohydrates within the eating regimen, frequently those that humans cannot digest and soak up.

Sleepiness (mainly after meals)

Weight advantage, fats storage, problem dropping weight – for the majority, extra weight is from high fat storage; the fats in IR is normally saved in and around belly organs in each women and men; it's miles presently suspected that [hormones](#) produced in that fats are a precipitating cause of insulin resistance ^[5].

Increased Blood Triglyceride Degrees

Increased blood pressure; many humans with hypertension are both diabetic and pre-diabetic and feature improved insulin stages because of insulin resistance; one of insulin's results is to govern arterial wall tension throughout the frame Increased pro-inflammatory cytokines associated with cardiovascular sickness [6-10].

[Depression](#) due to the deranged metabolism attributable to insulin resistance, psychological outcomes, consisting of despair, are not unusual.

Insulin Resistance in Type 2 Diabetes^[11-15]

[Open Access journals](#) model permits the dissemination of research articles to the worldwide community. It provides the advantage of interaction with the foremost effective minds from the scientific community.

The term "insulin resistance" commonly connotes resistance to the consequences of insulin on glucose uptake, metabolism, or garage. Insulin resistance in weight problems and type 2 diabetes is manifested through reduced insulin-stimulated glucose delivery and metabolism in adipocytes and skeletal muscle and with the aid of impaired suppression of hepatic glucose output (1). These practical defects may additionally end result, in element, from impaired insulin signalling in all three goal tissues and, in adipocytes, additionally from downregulation of the principal insulin-responsive glucose transporter, GLUT4. In each muscle and adipocytes, insulin binding to its receptor, receptor phosphorylation and tyrosine kinase interest, and phosphorylation of IRSs are reduced. There are also tissue-unique alterations: In adipocytes from overweight human beings with type 2 diabetes, IRS-1 expression is decreased, ensuing in decreased IRS-1-related PI3K activity, and IRS-2 will become the main docking protein for PI3K (14). In assessment, in skeletal muscle of overweight, type 2 diabetic topics, IRS-1 and IRS-2 protein tiers are normal however PI3K pastime related to both IRSs is impaired. [British Dietetic Association](#) specialist mass represents dietitians operating in adult and childhood obesity hindrance and management, recognising obesity as being a specialist in that field of dietetic practice. The obesity specialists works to speak evidence-based standards, support post-registration coaching for obesity management, contribute to national tips, campaign for health improvement, and to develop and foster a network of overweight management^[16-19]

One mechanism for the signaling defects in obesity may be the elevated expression and hobby of several protein tyrosine phosphatases (PTPs), which dephosphorylate and therefore terminate signaling propagated through tyrosyl phosphorylation occasions. Some statistics suggest that at least 3 PTPs, which includes PTP1B, leukocyte antigen-associated phosphatase (LAR), and src-homology-phosphatase 2, are accelerated in expression and/or hobby in muscle and [adipose tissue](#) ^[8-10] of overweight human beings and rodents (sixteen). PTP1B and LAR have been proven to dephosphorylate the insulin receptor and IRS-1 in vitro. In truth, mice in which PTP1B has been knocked out have expanded insulin sensitivity and resistance to food plan-induced obesity. At the least in component, due to increased strength expenditure. This indicates a regulatory role for PTP1B now not most effective in insulin movement, however additionally in power homeostasis. Interestingly, the insulin sensitivity is found in muscle and liver but now not in [adipocytes](#). Whether there's a causal dating among the insulin sensitivity and leanness/strength expenditure or whether or not those are regulated through unbiased signaling pathways is a key question. The information we can find more at [Canadian Obesity Network](#) ^[19-20].

Other mechanisms additionally make a contribution to insulin resistance in obesity. In morbid weight problems, the expression of various insulin signaling molecules is decreased in skeletal muscle ^[21-24]. In all forms of obesity and diabetes, a primary issue contributing to the impaired insulin-stimulated glucose transport in adipocytes is the downregulation of GLUT4. However, in skeletal muscle of overweight and diabetic human beings, GLUT4 expression is everyday (reviewed in ref. 21) and faulty glucose transport appears to be due to impaired translocation, docking, or fusion of GLUT4-containing vesicles with the plasma membrane ^[25-29].

Although insulin resistance is characteristic of [weight](#) problems and type 2 diabetes, it isn't hooked up that every one of insulin's movements are impaired in individuals with both situations. It is viable that hepatic lipogenesis and lipid garage are being pushed to extra in adipose tissue, whereas different insulin effects related to glucose homeostasis are impaired ^[30-33]. It will be essential to perceive the signaling pathways and transcription elements that could permit for such discordant moves of insulin.

The Significance of the Location of Body Fat for Insulin Resistance ^[33-50]

The courting between obesity and insulin resistance is seen throughout all ethnic businesses and is clear across the entire variety of body weights. Large epidemiologic studies monitor that the risk for diabetes, and presumably insulin resistance, rises as frame fats content (measured by frame mass index [BMI]) increases from the very lean to the very obese, implying that the “dose” of body fats has an effect on insulin sensitivity across a vast variety. Although this dating is visible with measures of adiposity together with BMI, which replicate well-known adiposity, it's miles important to realize that each one websites of adiposity are not same on this regard. Central (intra-belly) depots of fats are plenty greater strongly related to insulin resistance, [type 2 diabetes](#), and cardiovascular sickness than are peripheral (gluteal/subcutaneous) fats depots. This truth approximately fat and insulin sensitivity has now not been appropriately defined. It is possible that an unknown commonplace thing, both genetic and environmental, produces each insulin resistance and the important pattern of nearby adiposity and that critical weight problems does now not certainly motive [insulin](#) resistance. Alternatively, some biochemical function of intra-abdominal adipocytes can also at once have an impact on systemic insulin sensitivity.

A main hypothesis on this regard is that intra-stomach adipocytes are more lipolytically active, in part due to their supplement of adrenergic receptors. This might increase intraportal FFA levels and flux, which might inhibit insulin clearance and sell insulin resistance by using mechanisms that are nonetheless uncertain. Hyperinsulinemia in keeping with se can cause insulin resistance by way of downregulating insulin receptors and desensitizing postreceptor pathways, as became confirmed by overexpression of insulin in livers of otherwise ordinary transgenic mice. This [transgene](#) ended in an age-related discount in insulin receptor expression, glucose intolerance, and hyperlipidemia with none number one genetic disorder in insulin action or secretion (reviewed in ref. 29). An alternative speculation is that, due to the fact adipocytes are now regarded to secrete many elements which are able to exerting systemic outcomes (see underneath), the array of factors secreted by means of intra-stomach adipocytes may be specifically harmful to systemic insulin sensitivity. So far, this speculation stays unproven. Observation of extraordinary mitochondrial function in vitro in type 2 diabetes become quickly followed through in vivo demonstration of this abnormality in insulin-resistant, first-degree family of humans with type 2 diabetes (three). Further reviews of a modest illness in muscle mitochondrial feature in type 2 diabetes have been published rapidly thereafter (four, five). These studies raised the question of whether or not type 2 diabetes will be a primary disease of the mitochondria. However, the have a look at of first-degree spouse and children tended to be misinterpreted as having shown a chief illness in mitochondrial feature in type 2 diabetes, even though it had studied nondiabetic businesses from the alternative ends of the insulin resistance–sensitivity spectrum. Indeed, other studies showed no defect in mitochondrial feature in type 2 diabetes ^[51-59], which brought about similarly confusion. Mitochondrial function was then proven to be acutely modifiable through changing fatty acid availability (eight) and that it turned into suffering from ambient blood glucose concentration ^[60]. When ambient blood glucose tiers have been near ordinary in diabetes, no disorder in mitochondrial characteristic become apparent.

But if mitochondrial characteristic in properly-managed type 2 diabetes is not extraordinary, is a illness in insulin-resistant, first-degree spouse and children clinically applicable? The solution is provided in **Figure 1**, which shows populace distributions of insulin sensitivity for normoglycemia, impaired glucose tolerance, and type 2 diabetes. The extensive range of insulin sensitivity in the normoglycemic population absolutely encompasses the variety observed in type 2 diabetes. Even even though suggest insulin sensitivity in diabetes is lower than that of matched manage subjects, values are drawn from the same distribution and, with matching for frame weight and bodily hobby, differences might be rather small. Differences in [insulin](#) sensitivity will be in particular evident while making comparisons between groups selected from the acute ends of the population distribution (**Figure 1**). When parameters at once connected to muscle insulin resistance are as compared among companies selected in this way, any connected difference may be maximized, making this method entirely suitable to analyze the pathophysiology of muscle insulin resistance ^[60-70].




Figure 1: Populace distributions of insulin sensitivity for normoglycemia, impaired glucose tolerance, and type 2 diabetes.

More recent work using excessive calorie restriction showed previous findings and additionally proven an extended-time period return of regular insulin secretion as intrapancreatic fats content material fell. The fact that fasting and postprandial normoglycemia can be restored in type 2 diabetes without change in muscle insulin resistance must not be sudden. Mice totally missing in skeletal muscle insulin receptors do no longer develop diabetes (thirteen). People with inactive muscle glycogen synthase are not always hyperglycemic, and lots of normoglycemic people maintain regular blood glucose with a diploma of muscle insulin resistance equal to that among folks that increase [type 2 diabetes](#) (Figure 1). The relevance of muscle insulin resistance for improvement of type 2 diabetes is extra subtle. Over a few years and handiest in the presence of chronic calorie extra, hyperinsulinemia step by step brings about hepatic fats accumulation and hepatic insulin resistance. Onset of hyperglycemia is in the long run decided via failure of nutrient-stimulated insulin secretion [70-80]. This new information is defined by the dual cycle speculation. So what surely determines this vital number one insulin resistance in muscle?

Morino et al. [4] record analyses of mRNA in muscle biopsies to evaluate expression of genes worried in mitochondrial fatty acid oxidation. Their experiments evaluate information for topics at opposite extremes of the insulin resistance spectrum. Findings were showed in independent organizations selected within the same manner and two genes had been found to be consistently lower in expression. Using knock down of expression by way of appropriate inhibitory RNA, Western blotting showed that LPL became the important gene product. In each human rhabdomyosarcoma cells and L6 [myocytes](#), such knock down of LPL precipitated a decrease in mitochondrial density. The feature of LPL is to launch fatty acids from triglyceride for direct mobile uptake. The organic relevance of the hyperlink among reduced mitochondrial numbers and RNA interference ([RNAi](#)) inhibition of LPL changed into confirmed by means of looking at that the impact become only visible if fat become present inside the extracellular media. To check the speculation that fatty acid flux into cells regulates mitochondrial biogenesis with the aid of a PPAR-structured method, knock down of PPAR- δ was also shown to decrease mitochondrial density. Furthermore, problem of fatty acid uptake via directly inhibiting the transmembrane fatty transporter CD36 became shown to acquire the equal impact. Overall, these research propose that insulin resistance is associated with reduced mitochondrial content material in muscle due, at the least in component, to discounts in LPL expression and consequent reduced PPAR- δ activation.

This crucial article establishes a biological mechanism whereby insulin resistance in muscle is causally connected to genetic impacts which are measurable inside the wellknown population. It focuses on insulin resistance by means of evaluating extremes of the distribution of this feature within the everyday populace. But does insulin resistance motive mitochondrial disorder, or vice versa? The former appears more likely on the premise of cutting-edge evidence. Exercise can reduce insulin resistance and ameliorate mitochondrial disorder whereas installed mitochondrial disorder does not necessarily produce insulin resistance in animal models or in human beings [81-84].

Understanding the nature of common insulin resistance in muscle and its dating to type 2 diabetes is long late. Future work ought to determine whether particular [healing](#) manipulation can offset the impact of identifiable genetic affects and interrupt the longer term-in to type 2 diabetes [85-100].

REFERENCES

1. Shetty P. India faces growing breast cancer epidemic. See comment in PubMed Commons below Lancet. 2012;379:992-993.
2. WHO (World Health Organization). Global action plan for the prevention of non-communicable diseases 2013-2020.
3. WHO (World Health Organization). Obesity and overweight. 2014:311.
4. Paradis G. Have we lost the war on obesity? See comment in PubMed Commons below Can J Public Health. 2012;103:163.
5. Ginsburg OM, et al. The global cancer epidemic: opportunities for Canada in low- and middle-income countries. 2012;184:1699-1704.
6. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Design, Development and Therapy. 2011;5:325-380.
7. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management 2013;9:617-670.
8. Westley RL and May FE. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. See comment in PubMed Commons below Int J Endocrinol. 2013:632-461.
9. Sechang OH, et al. New Approach for Obesity Treatment Incorporating Individual Self-Management Education. J Obes Wt Loss Ther. 2013;3:164.
10. Slobod D and Fuks A. Military metaphors and friendly fire. See comment in PubMed Commons below CMAJ. 2012;184:144.
11. Kaplan RM. Behavioral epidemiology, health promotion, and health services. See comment in PubMed Commons below Med Care. 1985;23:564-583.
12. Kinch SH, et al. Risk factors in ischemic heart disease. A.J.P.H. 1963;53:438-442.
13. Skrabanek P. The death of humane medicine and the rise of coercive healthism. Social Affairs Unit, Edmunds, Suffolk. 1994.
14. Starfield B, et al. The concept of prevention: a good idea gone astray? See comment in PubMed Commons below J Epidemiol Community Health. 2008;62:580-583.
15. Saposnik G, et al. Heart Outcomes Prevention Evaluation 2 Investigators: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. See comment in PubMed Commons below Stroke. 2009;40:1365-1372.
16. Clinical Policy Bulletin: Cardiovascular Disease Risk tests.
17. Schwartz MW, et al. Central nervous system control of food intake. 2000;404:661-671.
18. Rodriguz-Artalejo F. Strengthening primordial and primary prevention of cardiovascular disease to increase life expectancy. Rev Esp Cardiol. 2013;66:837-838.
19. Garlapati S. A Highly Suggested Surgical Method for a Most Unwanted Problem -Bariatric Vs Obesity.J Obes Wt Loss Ther. 2012;2:104
20. Ozawa S and Sripad P. How do you measure trust in the health system? A systematic review of the literature. 2013;91:10-14.
21. Hafizuallah AM. Leptin: fights against obesity. Pak J Physiol. 2006;2:1-7.
22. Pasco JA, et al. Serum leptin levels are associated with bone mass in non-obese women. J Clin Endocrinol Metab. 2001; 86:1884-1887.
23. Fatima W, et al. Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int J Pediatr Obes. 2011;6:419-427.

24. Kenney RT, et al. 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé FondationMérieux, Annecy, France. *Vaccine*. 2002;20: 2155-2163.
25. Frühbeck G. Intracellular signalling pathways activated by leptin. *Biochem J*. 2006;393:7-20.
26. Hakansson-Ovesjo ML, et al. Downregulated STAT3 messenger ribonucleic acid and STAT3 protein in the hypothalamic arcuate nucleus of the obese leptin-deficient (ob/ob) mouse. *Endocrinology*. 2000;141:3946-3955.
27. Shimada M, et al. Mice lacking melanin-concentrating hormone are hypophagic and lean. 1998;396:670-674.
28. Montague CT, et al. Congenital leptin deficiency is associated with severe early onset obesity in humans. 1997;387:903-907.
29. Strobel A, et al. A leptin missense mutation associated with hypogonadism and morbid obesity. *Nat Genet*. 1998;18:213-215.
30. Mazen I, et al. A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient. *Mol Genet Metab*. 2009;97:305-308.
31. Fischer-Posovszky P, et al. A new missense mutation in the leptin gene causes mild obesity and hypogonadism without affecting T cellresponsiveness. *J ClinEndocrinolMetab*. 2010;95:2836-2840.
32. Wasim M and Fakhar N. Carrier Frequency of Congenital Leptin Deficiency in Central Punjab Region of Pakistan. *J Obes Weight Loss Ther*. 2015;5:260.
33. Farooqi IS, et al. Leptin regulates striatal regions and human eating behavior. *Science*. 2007;317:1355.
34. Heymsfield SB, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. *JAMA*. 1999;282:1568-1575.
35. Ahima RS. Revisiting leptin's role in obesity and weight loss. *J Clin Invest*. 2008;118:2380-2383.
36. Wasim M. Role of Leptin in Obesity. *J Obes Weight Loss Ther*. 2015;5:258.
37. Pediatric Anorexia Nervosa.
38. Fairfield WP, et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. *J ApplPhysiol*. 2001;90:2166-2171.
39. Tourkantonis I, et al. The Role of Leptin in Cancer Pathogenesis. *J Cancer Ther*. 2013;4:640-650.
40. Morgen CS and Sørensen TI. Obesity: global trends in the prevalence of overweight and obesity. *Nat Rev Endocrinol*. 2014;10:513-514.
41. World Health Organization. Fact Sheet #31, Obesity and Overweight, updated January, 2015.
42. Prentice AM. The emerging epidemic of obesity in developing countries. *Int J Epidemiol*. 2006;35:93-99.
43. Mendez MA, et al. Overweight exceeds underweight among women in most developing countries. *Am J ClinNutr*. 2005;81:714-721.
44. Global status report on non-communicable diseases 2010. Geneva, World Health Organization, 2012.
45. Rolls BJ, et al. What can intervention studies tell us about the relationship between fruit and vegetable consumption and weight management? *Nutr Rev*. 2004;62:1-17.
46. Luke A and Cooper RS. Physical activity does not influence obesity risk: time to clarify the public health message. *Int J Epidemiol*. 2013;42:1831-1836.
47. Dugas LR, et al. Energy expenditure in adults living in developing compared with industrialized countries: a meta-analysis of doubly labeled water studies. *Am J ClinNutr*. 2011;93:427-441.
48. Drewnowski A and Specter SE. Poverty and obesity: the role of energy density and energy costs. *Am J ClinNutr*. 2004;79:6-16.
49. Walker TB and Parker MJ. Lessons from the war on dietary fat. *J Am CollNutr*. 2014;33:347-351.
50. Kris-Etherton PM and Innis S. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids *J Am Diet Assoc*. 2007;107:1599-1611.
51. Kushi LH, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. *CA Cancer J Clin*. 2012;62: 30-37.
52. Gudzone KA, et al. Efficacy of commercial weight-loss programs: an updated systematic review. *Ann Intern Med*. 2015;162:501-512.
53. Atallah R, et al. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. *CircCardiovascQual Outcomes*. 2014;7:815-27.
54. Arora SK and McFarlane SI. The case for low carbohydrate diets in diabetes management. *NutrMetab*. 2005;2:16.

55. Llanos AAM, et al. Favorable effects of low-fat and low-carbohydrate dietary patterns on serum leptin, but not adiponectin, among overweight and obese premenopausal women: a randomized trial. *Springer Plus*. 2014;3:175-185.
56. Liu X,Zhang G, et al. Effects of a low-carbohydrate diet on weight loss and cardiometabolic profile in Chinese women: a randomised controlled feeding trial. *Br J Nutr*. 2013;110:1444-1453.
57. Kitabachi AE, et al. Effects of high-protein versus high carbohydrate diets on markers of B-cell function, oxidative stress, lipid peroxidation, proinflammatory cytokines, and adipokines in obese, premenopausal women without diabetes. A randomized controlled trial. *Diabetes Care*. 36:1919-1925.
58. Foster GD, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. *Ann Intern Med*. 2010;153:147-157.
59. De Luis DA, et al. Evaluation of weight loss and adipocytokine levels after two hypocaloric diets with different macronutrient distribution in obese subjects with rs6923761 gene variant of glucagon-like peptide 1 receptor. *Ann NutrMetab*. 2013;63:277-82.
60. Bazzano LA, et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. *Ann Intern Med*. 2014;161:309-318.
61. Ruth MR, et al. Consuming a hypocaloric high fat low carbohydrate diet for 12 weeks lowers C-reactive protein, and raises serum adiponectin and high density lipoprotein-cholesterol in obese subjects. *Metabolism*. 2013;62:1779-1787.
62. Dalle Grave R, et al. A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. *Obesity*. 2013;21:1774-1781.
63. Juanola-Falgarona M, et al. Effect of the glycemic index of the diet on weight loss, modulation of satiety, inflammation, and other metabolic risk factors: a randomized controlled trial. *Am J Clin Nutr*. 2014;100: 27-35.
64. Walker E, et al. Meta-analysis: Its strengths and limitations. *Cleve Clin J Med*. 2008;75:431-439.
65. Weigle DS, et al. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. *Am J ClinNutr*. 2005;82:41-48.
66. Santesso N, et al. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. *Eur J ClinNutr*. 2012;66:780-788.
67. Bosse JD and Dixon BM. Dietary protein in weight management: a review proposing protein spread and change theories. *NutrMetab*. 2012;9:81.
68. Clifton PM, et al. Long term weight maintenance after advice to consume low carbohydrate, higher protein diets—a systematic review and metaanalysis. *Nutr Metab Cardiovasc Dis*. 2014;24:224-235.
69. Hu T, et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. *Am J Epidemiol* 176 Suppl. 2012;7:44-54.
70. Hardt J, et al. Prevalence of Chronic Pain in a Representative Sample in the United States. *Pain Med*. 2008;9:803-812.
71. Jakobsson U, et al. Old people in pain: A comparative study. *J Pain Symptom Manage*. 2003;26:625-636.
72. Elliott AM, et al. The epidemiology of chronic pain in the community. *Lancet*. 1999;354:1248-1252.
73. Català E, et al. Prevalence of pain in the Spanish population: Telephone survey in 5,000 homes. *Eur J Pain*. 2002;6:133-140.
74. Rustøen T, et al. Prevalence and characteristics of chronic pain in the general Norwegian population. *Eur J Pain*. 2004;8:555-565.
75. Yu HY, et al. Prevalence, interference, and risk factors for chronic pain among Taiwanese community older people. *Pain Manag Nurs*. 2006;7:2-11.
76. Miró J, et al. Pain in older adults: A prevalence study in the Mediterranean region of Catalonia. *Eur J Pain*. 2007;11:83-92.
77. Loeser JD and Treede RD. The Kyoto Protocol of IASP Basic Pain Terminology. *Pain*. 2008;137:473-477.
78. Flegal KM, et al. Prevalence and Trends in Obesity among US Adults, 1999-2008. *JAMA*. 2010;303:235-241.
79. Hitt HC, et al. Comorbidity of obesity and pain in a general population: Results from the Southern Pain Prevalence Study. *J Pain*. 2007;8:430-436.
80. Andersen RE, et al. Relationship between body weight gain and significant knee, hip, and back pain in older Americans. *Obes Res*. 2003;11:1159-1162.

81. Tietjen GE, et al. Depression and anxiety: effect on the migraine-obesity relationship. *Headache*. 2007;47: 866-875.
82. Bigal ME, et al. Obesity and migraine: A population study. *Neurology*. 2006;66:545-550.
83. Scher AI, et al. Factors associated with the onset and remission of chronic daily headache in a population based study. *Pain*. 2003;106:81-89.
84. Marcus DA. Obesity and the impact of chronic pain. *Clin J Pain*. 2004;20:186-191.
85. Hurley RW and Adams MC. Sex, Gender, and Pain: An Overview of a Complex Field. *Anesth Analg*. 2008;107:309-317.
86. Riley JL III, et al. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. *Pain*. 1998;74:181-187.
87. Unruh AM. Gender variations in clinical pain experience. *Pain*. 1996;65:123-167.
88. Smith YR, et al. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. *J Neurosci*. 2006;26:5777-5785.
89. Ohayon MM and Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. *Arch Gen Psychiatry*. 2003;60:39-47.
90. Hardt J, et al. Prevalence of Chronic Pain in a Representative Sample in the United States. *Pain Med*. 2008;9:803-812.
91. Jakobsson U, et al. Old people in pain: A comparative study. *J Pain Symptom Manage*. 2003;26:625-636.
92. Elliott AM, et al. The epidemiology of chronic pain in the community. *Lancet*. 1999;354:1248-1252.
93. Català E, et al. Prevalence of pain in the Spanish population: Telephone survey in 5,000 homes. *Eur J Pain*. 2002;6:133-140.
94. Rustøen T, et al. Prevalence and characteristics of chronic pain in the general Norwegian population. *Eur J Pain*. 2004;8:555-565.
95. Yu HY, et al. Prevalence, interference, and risk factors for chronic pain among Taiwanese community older people. *Pain Manag Nurs*. 2006;7:2-11.
96. Miró J, et al. Pain in older adults: A prevalence study in the Mediterranean region of Catalonia. *Eur J Pain*. 2007;11:83-92.
97. Loeser JD and Treede RD. The Kyoto Protocol of IASP Basic Pain Terminology. *Pain*. 2008;137:473-477.
98. Dabrowska J, et al. The role of physical activity in preventing obesity in midlife women. *Prz Menopauzalny*. 2015;14:13-19.
99. Flegal KM, et al. Prevalence and Trends in Obesity among US Adults. 2010;303:235-241.
100. Hitt HC, et al. Comorbidity of obesity and pain in a general population: Results from the Southern Pain Prevalence Study. *J Pain*. 2007;8:430-436.